Related Experiment Video

Updated: Jun 13, 2026

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery
08:21

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery

Published on: June 28, 2019

Custom-designed proteins as novel therapeutic tools? The case of arrestins

Vsevolod V Gurevich1, Eugenia V Gurevich

  • 1Vanderbilt University, Nashville, TN 37232, USA. vsevolod.gurevich@vanderbilt.edu

Expert Reviews in Molecular Medicine
|April 24, 2010
PubMed

Insights

Researchers engineered a protein, arrestin1, to fix faulty signaling in genetic disorders. This custom protein mutant improves cell function and survival, offering a new therapeutic approach.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Genetics

Background:

  • Genetic disorders often involve overactive G-protein-coupled receptors (GPCRs) due to mutations.
  • These mutations can lead to constitutive activity or impaired desensitization by arrestins, disrupting cellular signaling.
  • Current understanding highlights the critical role of GPCR phosphorylation in arrestin-mediated desensitization.

Purpose of the Study:

  • To investigate the potential of modifying protein function for therapeutic benefit in genetic disorders.
  • To explore the use of arrestin1 as a tool to compensate for defective GPCR signaling.
  • To demonstrate proof-of-principle for custom protein design in treating signaling imbalances.

Main Methods:

  • Utilizing mechanistic understanding of protein function to engineer specific mutations.
  • Employing arrestin1's phosphorylation-independent capabilities to rescue defective rhodopsin signaling in retinal rod cells.
  • Investigating the manipulation of arrestin elements involved in scaffolding kinase cascades and protein-protein interactions.

Main Results:

  • Demonstrated that arrestin1 can compensate for impaired GPCR phosphorylation, restoring normal function.
  • Showcased improvements in light responsiveness and photoreceptor survival in a model system.
  • Identified potential for engineering arrestin mutants to influence cell survival and proliferation pathways.

Conclusions:

  • Targeted protein redesign based on mechanistic insights is a viable strategy for developing novel therapeutics.
  • Custom-designed protein mutants can correct aberrant signaling in genetic disorders.
  • This approach offers a promising new therapeutic toolbox for a range of congenital and acquired diseases.

More Related Videos

Parallel Interrogation of β-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-Tango Assay09:03

Parallel Interrogation of β-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-Tango Assay

Published on: March 10, 2020

Related Concept Videos

Assembly of Signaling Complexes01:30

Assembly of Signaling Complexes

Multiprotein signaling complexes are formed in a dynamic process involving protein-protein interactions at the cytoplasmic domain of transmembrane receptors or enzymatic and non-enzymatic proteins associated with the receptor. These complexes ensure the activation and propagation of intracellular signals that regulate cell functions.
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...
Allosteric Proteins-ATCase01:19

Allosteric Proteins-ATCase

Binding sites linkages can regulate a protein's function.  For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to  N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
Tail-anchoring of Proteins in the ER Membrane01:45

Tail-anchoring of Proteins in the ER Membrane

Tail-anchored, or TA, proteins are estimated to make up to 3-5% of membrane proteins found in the eukaryotic cell. Such proteins have a single transmembrane domain located approximately 30 amino acid residues upstream from the C-terminal end. As a result, the signal recognition particle (SRP) cannot guide a TA protein to the ER membrane for cotranslational insertion. Hence, they are integrated into the ER membrane post-translationally using their C-terminal end as the anchor. TA proteins...